Developer docs
API playgroundTry for free, no card

Search company profiles

AdhexPharma

Full company profile

uuid000sivb

Namestring
AdhexPharma
Legal namestring
ADHEXPHARMA (500 806 633 RCS Paris)
Websiteurl
adhexpharma.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

AdhexPharma is a privately held, France-headquartered pharmaceutical Contract Development and Manufacturing Organization (CDMO) that specializes in transdermal patches and oral films. The company delivers end-to-end services from drug concept through formulation development, analytical services, cGMP-compliant manufacturing, and licensing, serving both blue-chip pharmaceutical companies and innovative start-ups. Its technology platform centers on four proprietary drug delivery systems: Transfilm® (transdermal patches), Rapidfilm® (orodispersible oral films for gastrointestinal absorption), Mucofilm® (oromucosal buccal/sublingual films with limited industrial-scale competition), and Impregnated Matrix Patch technology. AdhexPharma currently manufactures eight approved products representing approximately 100 million units per year, with stated annual production capacity of 180 million units.

The business operates across four service lines: Contract Development, Contract Manufacturing, Analytical Services, and Licensing of branded products such as Nicopatchlib® (nicotine patch), Rivendo® (rivastigmine patch), and Zeqmelit® (dexamethasone oral film). Revenue is generated through project-based, quote-based B2B contracts — no standardized pricing is publicly disclosed — and the company emphasizes its ability to handle highly potent APIs, narcotics, and hormones under EMA, FDA, ISO 13485, 21 CFR Part 11, and 21 CFR Part 820 compliance. The Franco-German operational footprint combines French manufacturing (Paris HQ, Chenôve production) with German R&D and production acquired via Labtec GmbH (from tesa SE/Beiersdorf) in September 2022 and earlier AMW assets, creating a complementary cross-border CDMO platform. The company is owned by Burgundy Ventures, a French industrial holding, and was founded in 2007 to acquire the transdermal patch unit of Solvay in France. AdhexPharma is currently constructing a new 8,000 m² facility in Chenôve with completion targeted for end of 2025 and was prequalified for the France 2030 'Industrialization and Health Capacities' program.

Short descriptiontext

AdhexPharma is a France-based pharmaceutical CDMO specializing in transdermal patches and oral films, offering end-to-end development, manufacturing, analytical, and licensing services to blue-chip pharmaceutical companies and innovative start-ups across global markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersChenôve, France
HQ citystring
Chenôve
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
transdermal drug delivery, oral film manufacturing, pharmaceutical contract manufacturing, CDMO services, topical patch development
Industry1 code
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical CDMO Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Contract Development Services
TypeProfessional Services
Description

Full-service contract development from feasibility assessment through product development and clinical trial supply manufacturing to formulation transfer for commercial production

adhexpharma.com
2Contract Manufacturing Services
TypeProfessional Services
Description

cGMP-compliant manufacturing of transdermal patches and oral films for clinical trials and commercial markets. Handles entire supply chain from purchasing to packaging and storage.

adhexpharma.com
3Licensing
TypeLicensing Royalties
Description

Licensing opportunities for innovative products including Lidocaine/Prilocaine Impregnated Matrix Patch, Nicotine Matrix Patch (Nicopatchlib®), Rivastigmine Patch (Rivendo®), and Dexamethasone Oral Film (Zeqmelit®)

adhexpharma.com
4Analytical Services
TypeProfessional Services
Description

Comprehensive analytical support including method development, validation, transfer, quality control testing, release testing, stability storage and testing, with expertise in planar dosage forms analytics for patches and oral films

adhexpharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 7 records shown
1Mucofilm®
Description

Oral film technology designed for buccal or sublingual use with better absorption of the active ingredient and protection against copying. Can be designed for local treatment within the oral cavity or for systemic treatment of the whole body.

adhexpharma.com
+6 more records
Core offering1 text field

AdhexPharma is a full-service pharmaceutical CDMO specializing in the development and manufacturing of transdermal patches and oral films. The company provides end-to-end services from drug concept to market, including contract development, cGMP-compliant contract manufacturing, analytical services, and licensing of proprietary drug delivery technologies (Transfilm®, Rapidfilm®, Mucofilm®) and finished products (Nicopatchlib®, Rivendo®, Zeqmelit®). AdhexPharma serves both blue-chip pharmaceutical companies and innovative start-ups, manufacturing approximately 180 million units annually across 8 approved products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Manufacturing over 100 million units per year across 8 approved products
+3 more records
Product overview1 text field

AdhexPharma is a full-service CDMO (Contract Development and Manufacturing Organization) specializing in transdermal patches and oral films. The company offers a portfolio of proprietary drug delivery technologies including Rapidfilm® (orodispersible oral films for gastrointestinal absorption), Mucofilm® (oromucosal films for buccal/sublingual delivery), Transfilm® (transdermal patches), and Impregnated Matrix Patches. Beyond its own technologies, the company manufactures and licenses several approved products including Nicopatchlib® (nicotine patch), Rivendo® (rivastigmine patch), and Zeqmelit® (dexamethasone oral film). AdhexPharma provides integrated services spanning contract development, contract manufacturing, analytical services, and licensing, handling all steps from drug concept through commercial production.

Product and service1 record
1Rapidfilm®
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeOthersAnnounced on2024-03-22
Description

Architect firm for the new 8000m² facility in Chenôve, France. Contributing architectural innovation with tertiary spaces constructed with wooden framework.

2Croqüs
Strategic tierMinorTypeOthersAnnounced on2024-03-22
Description

Energy efficiency consultants for the new Chenôve facility. Ensuring the building meets the highest standards of sustainable construction and environmental regulations (RE2020).

adhexpharma.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-22
Description

AdhexPharma was selected as a prequalified candidate for the 'Industrialization and Health Capacities France 2030' project, underscoring the company's central role in the future of pharmaceutical manufacturing for essential and innovative medications.

Strategic tierMinorTypeOthersAnnounced on2022-09-16
Description

Engineering and building contractor for the construction of the new 8000m² state-of-the-art facility in Chenôve, France. The partnership supports AdhexPharma's facility expansion plans.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Lonza is one of the world's largest CDMOs across small molecules, biologics, and drug product services; it competes for broader CDMO engagements and increasingly for specialty dosage forms, including transdermal.

2Tapemark
TypeDirect peer
Description

Tapemark is a US-based contract developer and manufacturer of transdermal patches, topical formulations, and oral thin films, directly comparable to AdhexPharma's CDMO offering in patches and films.

3Recipharm
TypeBroad incumbent
Description

Recipharm is a European-headquartered contract developer and manufacturer of pharmaceuticals with broad drug product capabilities, representing a wider-incumbent comparable in the European CDMO market.

TypeBroad incumbent
Description

Catalent is a large global CDMO with a meaningful softgel, oral, and specialty drug delivery franchise; while not patch-specialist, it competes for adjacent CDMO work and represents the broader incumbent competitive backdrop.

TypeDirect peer
Description

Corium is a specialty transdermal and oral film CDMO focused on innovative drug delivery, including patches and dissolvable films, overlapping directly with AdhexPharma's technology and customer base.

6Vektor Pharma
TypeEmerging player
Description

Vektor Pharma is a German transdermal patch development specialist focused on innovative TDDS, comparable in geography and product focus to AdhexPharma's German operations via Labtec.

7AavantiBio / Osmotica Pharmaceutical (oral film)
TypeEmerging player
Description

Osmotica-affiliated entities have developed oral thin film products (e.g., ZolpiMist-style films), making them an emerging/specialty player in the orodispersible film space where AdhexPharma also competes.

TypeDirect peer
Description

Noven (a Hisamitsu subsidiary) specializes in transdermal drug delivery systems and is a longstanding direct peer in patch development and manufacturing, serving similar pharma clients with comparable dosage forms.

9ARx Solutions
TypeEmerging player
Description

ARx Solutions is a US-based specialty CDMO with expertise in transdermal and topical drug delivery, an emerging specialist peer in the same niche as AdhexPharma.

TypeDirect peer
Description

LTS is a leading global CDMO focused exclusively on transdermal patches and oral thin films, making it the closest direct competitor to AdhexPharma in both technology and customer base (pharma innovators seeking patch/film development and manufacturing).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AdhexPharma

Pharmaceutical CDMO Servicesadhexpharma.com

AdhexPharma is a France-based pharmaceutical CDMO specializing in transdermal patches and oral films, offering end-to-end development, manufacturing, analytical, and licensing services to blue-chip pharmaceutical companies and innovative start-ups across global markets.

What AdhexPharma does

AdhexPharma is a privately held, France-headquartered pharmaceutical Contract Development and Manufacturing Organization (CDMO) that specializes in transdermal patches and oral films. The company delivers end-to-end services from drug concept through formulation development, analytical services, cGMP-compliant manufacturing, and licensing, serving both blue-chip pharmaceutical companies and innovative start-ups. Its technology platform centers on four proprietary drug delivery systems: Transfilm® (transdermal patches), Rapidfilm® (orodispersible oral films for gastrointestinal absorption), Mucofilm® (oromucosal buccal/sublingual films with limited industrial-scale competition), and Impregnated Matrix Patch technology. AdhexPharma currently manufactures eight approved products representing approximately 100 million units per year, with stated annual production capacity of 180 million units.

The business operates across four service lines: Contract Development, Contract Manufacturing, Analytical Services, and Licensing of branded products such as Nicopatchlib® (nicotine patch), Rivendo® (rivastigmine patch), and Zeqmelit® (dexamethasone oral film). Revenue is generated through project-based, quote-based B2B contracts — no standardized pricing is publicly disclosed — and the company emphasizes its ability to handle highly potent APIs, narcotics, and hormones under EMA, FDA, ISO 13485, 21 CFR Part 11, and 21 CFR Part 820 compliance. The Franco-German operational footprint combines French manufacturing (Paris HQ, Chenôve production) with German R&D and production acquired via Labtec GmbH (from tesa SE/Beiersdorf) in September 2022 and earlier AMW assets, creating a complementary cross-border CDMO platform. The company is owned by Burgundy Ventures, a French industrial holding, and was founded in 2007 to acquire the transdermal patch unit of Solvay in France. AdhexPharma is currently constructing a new 8,000 m² facility in Chenôve with completion targeted for end of 2025 and was prequalified for the France 2030 'Industrialization and Health Capacities' program.

AdhexPharma firmographics

Firmographics
Name
AdhexPharma
Legal name
ADHEXPHARMA (500 806 633 RCS Paris)
Website
https://adhexpharma.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
101–250 employees
Short description
AdhexPharma is a France-based pharmaceutical CDMO specializing in transdermal patches and oral films, offering end-to-end development, manufacturing, analytical, and licensing services to blue-chip pharmaceutical companies and innovative start-ups across global markets.
Ownership category
akta.pro rank

AdhexPharma industry classification

Industry
Product category
Pharmaceutical CDMO Services
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Transdermal drug delivery
  • Oral film manufacturing
  • Pharmaceutical contract manufacturing
  • CDMO services
  • Topical patch development

Where AdhexPharma is headquartered

Location

Headquarters

HQ city
Chenôve
HQ country
France
HQ region
Europe

Offices4 records

Markets served

AdhexPharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Development Services: Full-service contract development from feasibility assessment through product development and clinical trial supply manufacturing to formulation transfer for commercial production
  2. Contract Manufacturing Services: cGMP-compliant manufacturing of transdermal patches and oral films for clinical trials and commercial markets. Handles entire supply chain from purchasing to packaging and storage.
  3. Licensing: Licensing opportunities for innovative products including Lidocaine/Prilocaine Impregnated Matrix Patch, Nicotine Matrix Patch (Nicopatchlib®), Rivastigmine Patch (Rivendo®), and Dexamethasone Oral Film (Zeqmelit®)
  4. Analytical Services: Comprehensive analytical support including method development, validation, transfer, quality control testing, release testing, stability storage and testing, with expertise in planar dosage forms analytics for patches and oral films

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

AdhexPharma product offering

Product offering

Core offering

AdhexPharma is a full-service pharmaceutical CDMO specializing in the development and manufacturing of transdermal patches and oral films. The company provides end-to-end services from drug concept to market, including contract development, cGMP-compliant contract manufacturing, analytical services, and licensing of proprietary drug delivery technologies (Transfilm®, Rapidfilm®, Mucofilm®) and finished products (Nicopatchlib®, Rivendo®, Zeqmelit®). AdhexPharma serves both blue-chip pharmaceutical companies and innovative start-ups, manufacturing approximately 180 million units annually across 8 approved products.

Product overview

AdhexPharma is a full-service CDMO (Contract Development and Manufacturing Organization) specializing in transdermal patches and oral films. The company offers a portfolio of proprietary drug delivery technologies including Rapidfilm® (orodispersible oral films for gastrointestinal absorption), Mucofilm® (oromucosal films for buccal/sublingual delivery), Transfilm® (transdermal patches), and Impregnated Matrix Patches. Beyond its own technologies, the company manufactures and licenses several approved products including Nicopatchlib® (nicotine patch), Rivendo® (rivastigmine patch), and Zeqmelit® (dexamethasone oral film). AdhexPharma provides integrated services spanning contract development, contract manufacturing, analytical services, and licensing, handling all steps from drug concept through commercial production.

Differentiator

Problem solved

Functional benefit

Brands

  • Mucofilm®: Oral film technology designed for buccal or sublingual use with better absorption of the active ingredient and protection against copying. Can be designed for local treatment within the oral cavity or for systemic treatment of the whole body.
  • Rapidfilm®
  • Transfilm®
  • Nicopatchlib®
  • Rivendo®
  • Zeqmelit®
  • Lidocaine/Prilocaine Impregnated Matrix Patch

Products and services

  • Rapidfilm®

Quantifiable outcome

  • Manufacturing over 100 million units per year across 8 approved products
  • +3 more outcomes

Companies that use AdhexPharma

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles1 record

AdhexPharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

AdhexPharma partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • Studio MustardminorOthers · 22 March 2024Architect firm for the new 8000m² facility in Chenôve, France. Contributing architectural innovation with tertiary spaces constructed with wooden framework.
  • CroqüsminorOthers · 22 March 2024Energy efficiency consultants for the new Chenôve facility. Ensuring the building meets the highest standards of sustainable construction and environmental regulations (RE2020).
  • France 2030coreStrategic or Co-development Partner · 22 March 2024AdhexPharma was selected as a prequalified candidate for the 'Industrialization and Health Capacities France 2030' project, underscoring the company's central role in the future of pharmaceutical manufacturing for essential and innovative medications.
  • Groupe GuitonminorOthers · 16 September 2022Engineering and building contractor for the construction of the new 8000m² state-of-the-art facility in Chenôve, France. The partnership supports AdhexPharma's facility expansion plans.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

AdhexPharma competitors and assessment

Company assessment

Broad incumbents

  • Lonza Group: Lonza is one of the world's largest CDMOs across small molecules, biologics, and drug product services; it competes for broader CDMO engagements and increasingly for specialty dosage forms, including transdermal.
  • Recipharm: Recipharm is a European-headquartered contract developer and manufacturer of pharmaceuticals with broad drug product capabilities, representing a wider-incumbent comparable in the European CDMO market.
  • Catalent (Novo Holdings): Catalent is a large global CDMO with a meaningful softgel, oral, and specialty drug delivery franchise; while not patch-specialist, it competes for adjacent CDMO work and represents the broader incumbent competitive backdrop.

Direct peers

  • Tapemark: Tapemark is a US-based contract developer and manufacturer of transdermal patches, topical formulations, and oral thin films, directly comparable to AdhexPharma's CDMO offering in patches and films.
  • Corium (Gurnet Point Capital): Corium is a specialty transdermal and oral film CDMO focused on innovative drug delivery, including patches and dissolvable films, overlapping directly with AdhexPharma's technology and customer base.
  • Noven Pharmaceuticals: Noven (a Hisamitsu subsidiary) specializes in transdermal drug delivery systems and is a longstanding direct peer in patch development and manufacturing, serving similar pharma clients with comparable dosage forms.
  • LTS Lohmann Therapie-Systeme: LTS is a leading global CDMO focused exclusively on transdermal patches and oral thin films, making it the closest direct competitor to AdhexPharma in both technology and customer base (pharma innovators seeking patch/film development and manufacturing).

Emerging players

  • Vektor Pharma: Vektor Pharma is a German transdermal patch development specialist focused on innovative TDDS, comparable in geography and product focus to AdhexPharma's German operations via Labtec.
  • AavantiBio / Osmotica Pharmaceutical (oral film): Osmotica-affiliated entities have developed oral thin film products (e.g., ZolpiMist-style films), making them an emerging/specialty player in the orodispersible film space where AdhexPharma also competes.
  • ARx Solutions: ARx Solutions is a US-based specialty CDMO with expertise in transdermal and topical drug delivery, an emerging specialist peer in the same niche as AdhexPharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

AdhexPharma social profiles

Digital presence

AdhexPharma compliance and trust

Trust signal

Compliance6 records

AdhexPharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AdhexPharma leadership team

Management profile

Number of profiles

Profiles5 records

AdhexPharma subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

AdhexPharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AdhexPharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AdhexPharma

What does AdhexPharma do?

AdhexPharma is a full-service pharmaceutical CDMO specializing in the development and manufacturing of transdermal patches and oral films. The company provides end-to-end services from drug concept to market, including contract development, cGMP-compliant contract manufacturing, analytical services, and licensing of proprietary drug delivery technologies (Transfilm®, Rapidfilm®, Mucofilm®) and finished products (Nicopatchlib®, Rivendo®, Zeqmelit®). AdhexPharma serves both blue-chip pharmaceutical companies and innovative start-ups, manufacturing approximately 180 million units annually across 8 approved products.

Is AdhexPharma a public or private company?

AdhexPharma is a private company. It is classified as corporate owned and is currently operating.

When was AdhexPharma founded?

AdhexPharma was founded in 2007. It employs 101 to 250 people.

Where is AdhexPharma based?

AdhexPharma is headquartered in Chenôve, France, in the Europe region.

How does AdhexPharma make money?

Four revenue lines are on record. Contract Development Services are the primary driver. The others are contract Manufacturing Services, licensing and analytical Services.

Who are AdhexPharma's main competitors?

Broad incumbents on record are Lonza Group, Recipharm and Catalent (Novo Holdings). Direct peers are Tapemark, Corium (Gurnet Point Capital), Noven Pharmaceuticals and LTS Lohmann Therapie-Systeme. Emerging players are Vektor Pharma, AavantiBio / Osmotica Pharmaceutical (oral film) and ARx Solutions.

Does AdhexPharma have an API?

No public API is recorded for AdhexPharma.

What industry is AdhexPharma in?

AdhexPharma's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales